<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437175</url>
  </required_header>
  <id_info>
    <org_study_id>Pronutri-IIIa-001</org_study_id>
    <nct_id>NCT02437175</nct_id>
  </id_info>
  <brief_title>Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study</brief_title>
  <official_title>Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Pronutri</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Expert Clinical Services Organization (ECSOR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoires Pronutri</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this pilot study is to evaluate the efficacy of trace elements,&#xD;
      versus placebo, on the reduction of pain in endometriosis of an American Fertility Society&#xD;
      (AFSr) score of 2 to 4, combined or not to an adenomyosis, during a chronic treatment of 4&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this pilot study are to evaluate the efficacy of trace elements, versus&#xD;
      placebo, on the reduction of pain, on the quality of life, on the use of rescue medication&#xD;
      (ibuprofen) in patients with an endometriosis of an American Fertility Society (AFSr) score&#xD;
      of 2 to 4, combined or not to an adenomyosis, during a chronic treatment of 4 months. The&#xD;
      safety of trace elements versus placebo will also be assessed.&#xD;
&#xD;
      This will be a prospective, interventional, randomized, placebo-controlled, two&#xD;
      parallel-group, double-blind study.&#xD;
&#xD;
      Trace elements or placebo are administered in the absence of any other treatment or as add-on&#xD;
      treatments to common therapies such as sexual hormones, anti-inflammatory drugs or surgery.&#xD;
&#xD;
      A run-in placebo period of 30 days will allow eliminating the patients who are responding to&#xD;
      strongly to a placebo.&#xD;
&#xD;
      The treatment will last for 4 months. The total duration of the study will be 5 months for&#xD;
      each patient. Four medical visits (Days -45 to -30, 0, 60 and 120) and two phone contacts&#xD;
      (Days 30 and 90) will be scheduled.&#xD;
&#xD;
      A urine pregnancy test will be undertaken at each visit. The quality of life scale (EHP-30)&#xD;
      will be filled in on Days 0, 60 and 120. During the whole study period, patients will be&#xD;
      asked to fill in a diary, in which they will score their pain on a visual analog scale, their&#xD;
      blood loss and their consumption of rescue medication (ibuprofen).&#xD;
&#xD;
      Phone contacts will be used to reinforce the compliance and to collect potential adverse&#xD;
      events.&#xD;
&#xD;
      Non-serious and serious adverse events will be collected between Days 0 and 120.&#xD;
&#xD;
      All concomitant medications will be recorded, including the rescue medication between Day -45&#xD;
      and Day 120.&#xD;
&#xD;
      A paper case report form will be used.&#xD;
&#xD;
      A total of 60 patients (30 receiving trace elements and 30 receiving placebo) will be&#xD;
      randomized to achieve a total of 50 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain (visual analog scale)</measure>
    <time_frame>Day 0 to Day 120</time_frame>
    <description>Pain scored daily by the patient using a visual analog scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EHP-30 (validated 30-items questionnaire)</measure>
    <time_frame>Day 0 to Day 120</time_frame>
    <description>Quality of life determined using a validated 30-items questionnaire (EHP-30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication consumption (Number of ibuprofen tablets consumed)</measure>
    <time_frame>Day 0 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Non-serious and serious adverse events (related or not)</measure>
    <time_frame>Day 0 to Day 120</time_frame>
    <description>Non-serious and serious adverse events (related or not)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trace elements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ENDO 1/ENDO 2</intervention_name>
    <description>NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.</description>
    <arm_group_label>Trace elements</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Woman suffering from an AFSr 2 to 4 endometriosis (combined or not to an adenomyosis),&#xD;
             confirmed by laparoscopy, laparotomy or MRI as well as by a biopsy (done within 3&#xD;
             years before inclusion in the study), treated or not with sexual hormones,&#xD;
             contraceptive or not (stable treatment for minimum 2 months) or any other treatment&#xD;
&#xD;
          -  Time period of at least 6 months after surgical treatment&#xD;
&#xD;
          -  Age between 18 and 45 years&#xD;
&#xD;
          -  Non-menopausal woman&#xD;
&#xD;
          -  Baseline pain (Day -45 to -30) of at least 40 mm on a visual analog scale&#xD;
&#xD;
          -  No reduction of more than 20% of pain on the visual analog scale after the run-in&#xD;
             placebo period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AFSr 1 endometriosis&#xD;
&#xD;
          -  Adenomyosis without endometriosis&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Existence of another pathology that could interfere with endometriosis and/or with&#xD;
             adenomyosis, and the study follow-up&#xD;
&#xD;
          -  Psychological or psychiatric conditions&#xD;
&#xD;
          -  Patient who, according to the investigator, will not be able to comply to the&#xD;
             prerequisites of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Oberweis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Vésale</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Vésale</name>
      <address>
        <city>Montigny-le-Tilleul</city>
        <state>Hainaut</state>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.dovepress.com/articles.php?article_id=25534</url>
    <description>A pilot double-blind, randomized, placebo-controlled trial of the efficacy of trace elements in the treatment of endometriosis-related pain: study design and methodology</description>
  </link>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pelvic pain</keyword>
  <keyword>quality of life</keyword>
  <keyword>adenomyosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Methodology paper</doc_type>
      <doc_url>https://www.dovepress.com/articles.php?article_id=25534</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

